Second-line Treatment of Metastatic Colorectal Cancer - Trial NCT06242067
Access comprehensive clinical trial information for NCT06242067 through Pure Global AI's free database. This Phase 2 trial is sponsored by Qilu Hospital of Shandong University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Qilu Hospital of Shandong University
Timeline & Enrollment
Phase 2
Apr 23, 2023
Dec 01, 2026
Primary Outcome
progression-free survival(PFS)
Summary
The goal of this multicenter, single-arm, observational cohort study is to investigate the
 efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab
 in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy
 (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of
 recurrence.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06242067
Non-Device Trial